Skip to main content
. 2012 Jan 13;74(1):75–85. doi: 10.1111/j.1365-2125.2012.04173.x

Figure 2.

Figure 2

Median DPP-4 inhibition after single oral doses of 5 mg linagliptin in patients with different degrees of hepatic function. Normal hepatic function (n = 8) (Inline graphic); Mild hepatic impairment (n = 8) (Inline graphic); Moderate hepatic impairment (n = 9) (Inline graphic); Severe hepatic impairment (n = 8) (Inline graphic)